AstraZeneca (AZN) stock is in focus as the company's experimental drug gefurulimab for generalized myasthenia gravis hits Phase 3 trial goals. Read more here.

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a late-stage study aimed at improving symptoms of a rare autoimmune ...

AstraZeneca plans to invest $50 billion in U.S. operations by 2030, including a new facility in Virginia. Petersburg, Virginia is a potential location for the new AstraZeneca facility due to its ...

The state of Maryland and the Moore Administration can best be characterized as “whistling past the graveyard” once again … case in point: The Virginia Mercury headline (July 22, 2025) … “AstraZeneca ...

Both AstraZeneca’s and argenx’s stock prices were up about 1.2% in morning trading following the news. The PREVAIL announcement follows a week of newsmaking for AstraZeneca. The company stumbled last ...

AstraZeneca investing in multi-billion dollar facility in Virginia The pharmaceutical giant is choosing where in the commonwealth it will build the new facility The API failed to deliver the resource.

Youngkin boasts Virginia's shovel-ready sites and workforce as key in luring AstraZeneca AstraZeneca selected Virginia for its largest global manufacturing investment, boosting local job prospects.

International Business News: AstraZeneca is set to invest $50 billion in the U.S., featuring a large manufacturing plant in Virginia, marking its biggest manufacturing investment.

Drug maker AstraZeneca has announced plans to invest 50 billion dollars (£37 billion) in the US over the next five years amid the looming threat of President Donald Trump’s trade tariffs.

AstraZeneca to spend $50 billion in US production build out to avert tariff threat Texas, Virginia, Indiana and Massachusetts are all part of the drugmaker’s plans.

AstraZeneca to build largest US plant in Virginia as part of $50B investment in US President Donald Trump referenced the announcement the following day in Oval Office remarks, framing AstraZeneca’s ...

Ahead of the 10-year anniversary of Tagrisso’s FDA approval this fall, AstraZeneca has debuted the first DTC commercial for the lung cancer med.